Compare RNST & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RNST | TVTX |
|---|---|---|
| Founded | 1904 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 2.8B |
| IPO Year | 1994 | 2013 |
| Metric | RNST | TVTX |
|---|---|---|
| Price | $40.49 | $40.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 14 |
| Target Price | ★ $42.25 | $40.46 |
| AVG Volume (30 Days) | 597.1K | ★ 2.3M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.27% | N/A |
| EPS Growth | N/A | ★ 92.89 |
| EPS | ★ 2.07 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $31.72 | $43.88 |
| Revenue Next Year | $4.67 | $33.16 |
| P/E Ratio | $19.56 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $27.85 | $13.88 |
| 52 Week High | $42.11 | $43.31 |
| Indicator | RNST | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 69.58 | 68.21 |
| Support Level | $35.26 | $32.62 |
| Resistance Level | $42.11 | $41.44 |
| Average True Range (ATR) | 1.00 | 2.21 |
| MACD | 0.36 | 1.17 |
| Stochastic Oscillator | 89.27 | 79.70 |
Renasant Corp operates as a holding company for Renasant Bank, a Mississippi banking corporation, and its subsidiary, Renasant Insurance, Inc. It has three reportable segments: Community banks, Insurance, and Wealth management. With its Community banks segment, the company provides a range of financial services to individuals and small businesses. Its Insurance segment is an insurance agency providing commercial and personal insurance through third-party carriers. The Wealth management segment provides a range of services, including money management and retirement planning. The majority of the company's revenue is driven by lending activities in its community banks segment.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.